Graham Cooksley
The University of Queensland · 56 works · 6,001 citations · h-index 27
Top works
- The Natural History of Nonalcoholic Steatohepatitis: A Follow–Up Study of Forty–Two Patients for Up to 21 Years
- Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
- Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
- Hepatitis A booster vaccination: is there a need?
- HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
- Body composition in nonalcoholic cirrhosis: The effect of disease etiology and severity on nutritional compartments
- Robust antiviral activity of R1626, a novel nucleoside analog
- The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C
- Comparative study of three doses of interferon‐α2a in chronic active hepatitis B
- Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine
- Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users
- Frequency of Mutation and Deletion of the Tumor Suppressor Gene Cdkn2a (Mts1/P16) in Hepatocellular Carcinoma From An Australian Population
- Treatment of non‐resectable hepatocellular carcinoma with autologous tumor‐pulsed dendritic cells
- Re‐treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon‐alpha‐2a (40 kDa) and ribavirin
- Hepatitis A virus: declining seroprevalence in children and adolescents in Southeast Asia.
- 731 Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting hcv polymerase in chronic HCV patients
- Hepatitis B vaccine boosters: Is there a clinical need in high endemicity populations?
- Cost-Effectiveness of Combination Peginterferon alpha-2a and Ribavirin Compared With Interferon alpha-2b and Ribavirin in Patients With Chronic Hepatitis C
- HBV core sequence: definition of genotype‐specific variability and correlation with geographical origin
- 50 Durability of response and occurrence of late response to peginterferon alpha-2a (40KD) [PEGASYS] one year post-treatment in patients with HBeAg-positive chronic hepatitis B